New drug cocktail shows promise for Tough-to-Treat uterine cancer
NCT ID NCT03694262
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study is now complete, and results will help determine if this approach is worth testing in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rucaparib, bevacizumab, and atezolizumab (drug combination)
What this could lead to
If successful, this drug combination could offer a new treatment option for people with recurrent endometrial cancer that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial (30 people) without a comparison group, so results may not apply broadly. The combination may cause significant side effects and may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
-
Mount Sinai
New York, New York, 10029, United States
-
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015, United States